CytomX Therapeutics, Inc. Cash and Restricted Cash
CytomX Therapeutics, Inc. (CTMX) had Cash and Restricted Cash of $189.34 million as of 2019-12-31, per its 10-K filed 2020-02-27.
Discontinued › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2020-02-27
- 2019-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $189.34M.
- 2018-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $248.49M.
- 2018-09-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $260.67M.
- 2018-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $133.82M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents |
|---|---|
| 2019-12-31 | $189.34M 10-K · filed 2020-02-27 |
| 2018-12-31 | $248.49M 10-K · filed 2020-02-27 |
| 2018-09-30 | $260.67M 10-Q · filed 2018-11-06 |
| 2018-06-30 | $133.82M 10-Q · filed 2018-08-08 |
| 2018-03-31 | $143.07M 10-Q · filed 2018-05-09 |
| 2017-12-31 | $178.47M 10-K · filed 2019-02-27 |
| 2017-09-30 | $285.14M 10-Q · filed 2018-11-06 |
| 2017-06-30 | $273.78M 10-Q · filed 2018-08-08 |
| 2017-03-31 | $86.58M 10-Q · filed 2018-05-09 |
| 2016-12-31 | $105.56M 10-K · filed 2019-02-27 |
| 2015-12-31 | $60.74M 10-K · filed 2019-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B |